Rheumatoid arthritis is among the most common arthritic diseases, with 71 cases diagnosed per 100,000 people. To alleviate symptoms and reduce long-term damage, treatment options available to patients include biologics, particularly adalimumab (Humira)-a tumor necrosis factor inhibitor. The drug has played a vital role in the treatment of rheumatoid arthritis over the years, but recently adalimumab-adbm (Cyltezo) was developed as the first interchangeable biosimilar that mimics the structure and function of the original product.
展开▼
